Dual-targeting agents, such as the bispecific anti-Ang2/VEGF-A antibody A2V, have shown promise in normalizing tumor vasculature while simultaneously reprogramming the TME (Kloepper et al., 2016). Here, VEGFA is linked to neoplasm.